KATHERINE CHANG: Open Payments
NPI 1912225384 · CORPUS CHRISTI, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,528 in 52 payments from 15 companies in 2025. Trend: 2023 $858 · 2024 $1,032 · 2025 $1,528
Food & beverage: $1,458Education: $70
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $480 |
| Galderma Laboratories, L.P. | 11 | $226 |
| Regeneron Healthcare Solutions, Inc. | 5 | $177 |
| GENZYME CORPORATION | 1 | $122 |
| GlaxoSmithKline, LLC. | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $104 |
| Organon LLC | 3 | $103 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| Lilly USA, LLC | 1 | $28 |
| Octapharma USA, Inc. | 1 | $25 |
Products named: DUPIXENT, NEMLUVIO, TEZSPIRE, CUVITRU, FASENRA, VTAMA, TRELEGY ELLIPTA, NUCALA.
Industry payments across TX — which companies pay providers there.
